RecruitingNCT02579278

Circulating Tumour DNA (ctDNA) in Patients With Colorectal Cancer and the Relationship to Imaging Features of Extramural Venous Invasion

Sponsor

Imperial College London

Enrollment

100 participants

Start Date

Nov 1, 2015

Study Type

OBSERVATIONAL

Conditions

Cancer Rectal Cancer

Summary

This study does not involve randomization or treatment. Eligible patients have colorectal adenocarcinoma with no metastases eligible for curative surgery. A pre operative staging scan must have been completed within 6 weeks prior to surgery. Two x 20ml blood samples will be taken from each patient, one prior to and one during or within 24hrs after surgery. Patients are annually followed up to 3 years.

Eligibility

Min Age: 16 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at whether pieces of tumor DNA floating in the blood (called circulating tumor DNA or ctDNA) can predict how likely colorectal cancer is to come back after surgery, and whether a tumor feature seen on CT scans (called extramural venous invasion) relates to the amount of ctDNA found. **You may be eligible if...** - You are 16 years of age or older - You have been diagnosed with colorectal cancer confirmed by biopsy - Your cancer has not spread to other parts of the body (non-metastatic) - You are eligible for surgery with the goal of curing your cancer - You have had a staging scan within 6 weeks before your planned surgery - You have given written informed consent **You may NOT be eligible if...** - Your cancer has spread to other organs (including resectable liver metastases) - You have a second cancer at the same time - You have conditions that prevent any imaging to assess cancer spread Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBlood sample (mrEMVI positive patient)

Two blood samples are taken from each patient with mrEMVI positive tumours post chemoradiotherapy. One pre-surgery and one during surgery from a peripheral vein.

OTHERBlood sample (mrEMVI negative patient)